Global Tramadol Market Research Report 2022

Due to the COVID-19 pandemic, the global Tramadol market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Tramadol market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Tramadol landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Oral Type Tramadol accounting for % of the Tramadol global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Tramadol include CSL Limited, Grnenthal GmbH, Mundipharma, Hexal AG, Labopharm, Pliva Pharma, Nippon Shinyaku, Atoz Pharmaceuticals and Rompharm Company, etc. In terms of revenue, the global 3 largest players have a % market share of Tramadol in 2021.
This report focuses on Tramadol volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Tramadol market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Tramadol Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Sale Channel. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Oral Type Tramadol
Injection Type Tramadol
Segment by Sale Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
CSL Limited
Grnenthal GmbH
Mundipharma
Hexal AG
Labopharm
Pliva Pharma
Nippon Shinyaku
Atoz Pharmaceuticals
Rompharm Company
Amneal Pharmaceuticals
Par Pharmaceutical
Kosher Pharmaceuticals
CSPC
Xinhua Pharmaceutical
Tianlong Shiye
Southwest Pharmaceutical

Frequently Asked Questions